Jump to content

Design, Generation, and Evaluation of TCR-, TCR mimetic- and CAR-based Therapeutics for Cancer Immunotherapy

PEGS Boston, Boston, MA, USA
May 8, 2020

TCRs, antibody TCR-mimetics, CARs can provide significant advantages over traditional mAb approaches for the treatment of cancer.  However, as highly engineered entities, they pose new design, cloning, expression, purification, and analytics challenges. Our workflow platform, employed by top biopharma companies, enables the automation, engineering, production, and testing of large panels of these candidate therapeutic molecules. We demonstrate the platform’s high-throughput capability when handling novel molecule-specific designs and its built-in tools for developability and manufacturability assessments.

Request Resource

By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Genedata privacy policy